Form 4: Coeptis Therapeutics CFO Brian Cogley Receives Stock Options Grant

Brian Cogley, CFO of Coeptis Therapeutics Holdings, Inc., was granted 10,000 non-qualified stock options on March 4, 2025, under the company's 2022 equity incentive plan.

Summary

• On March 4, 2025, Brian Cogley, the Chief Financial Officer of Coeptis Therapeutics Holdings, Inc., received a grant of 10,000 non-qualified stock options.
• These options were granted under the company's 2022 equity incentive plan.
• The exercise price of the options is $10.56, which is equal to the company's stock price on the Nasdaq Capital Market on the day of the grant.
• The options will vest over four years in equal quarterly installments, with the final vesting date on December 31, 2028.
• The options expire ten years from the grant date.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard practice and indicates confidence in the company's future performance, but it's not a major event.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen typically use stock options as part of their compensation strategy to incentivize key executives.
• The vesting schedule of four years with quarterly installments is also a common practice.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with theirs.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates